Generic Name and Formulations:
Granisetron extended-release 10mg/0.4mL; per pre-filled syringe; viscous liq for SC inj.
Indications for SUSTOL:
In combination with other antiemetics, to prevent acute and delayed nausea/vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination regimens.
Give as a slow, SC inj over 20–30secs with IV dexamethasone ≥30mins before chemotherapy. ≥18yrs: 10mg on Day 1 of chemotherapy; give no sooner than once every 7 days. For MEC: use IV dexamethasone 8mg on Day 1. For AC: use IV dexamethasone 20mg on Day 1, then 8mg orally twice daily on Days 2–4. If concomitant NK1 receptor antagonist: see full labeling. Renal impairment (CrCl 30–59mL/min): give Sustol on Day 1 of chemotherapy and no sooner than once every 14 days; (CrCl <30mL/min): avoid.
<18yrs: not established.
Hypersensitivity to other 5-HT3 receptor antagonists.
Monitor for inj site reactions (including infections, bruising/hematoma, bleeding, others); if ongoing or unresolved reactions, administer in unaffected areas. Abdominal surgery. May mask progressive ileus and/or gastric distention. GI obstruction. Monitor for constipation, decreased bowel activity. Monitor for serotonin syndrome; discontinue if symptoms occur. Renal impairment. Pregnancy. Nursing mothers.
Increased risk of severe bruising and/or hematoma with concomitant antiplatelets or anticoagulants. Increased risk of serotonin syndrome with concomitant other SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, or IV methylene blue.
Selective 5-HT3 receptor antagonist.
Inj site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, gastroesophageal reflux; hypersensitivity, serotonin syndrome.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML